Immunogenicity and Safety Study of GSK Biologicals' Meningococcal Vaccine Given as One Dose to Healthy Subjects Above 56 Years

GlaxoSmithKline400 enrolled

Overview

This study evaluates the immunogenicity and safety of the meningococcal conjugate vaccine GSK 134612 given as single dose to healthy adults 56 years or older compared to the meningococcal polysaccharide vaccine MencevaxACWYTM.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

PREVENTION

Masking

NONE

Enrollment

400

Conditions

Infections, Meningococcal

Interventions

Meningococcal vaccine GSK 134612BIOLOGICAL

Intramuscular injection

MencevaxACWY TMBIOLOGICAL

Subcutaneous injection

Eligibility

Sex: ALLMin age: 56 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Subjects who the investigator believes can and will comply with the requirements of the protocol * A male or female 56 years of age or older at the time of the vaccination. * Written informed consent obtained from the subject. * Female subjects of non-childbearing potential may be enrolled in the study. * Non-child-bearing potential is defined as current tubal ligation, hysterectomy, ovariectomy or post-menopause. Exclusion Criteria: * Use of any investigational or non-registered product other than the study vaccine(s) within 30 days preceding the first dose of study vaccine, or planned use during the study period. * Concurrent participation in another clinical study, at any time during the study period, in which the subject has been or will be exposed to an investigational or non-investigational product. * Extended administration of immunosuppressants or other immune-modifying drugs within six months prior to the vaccination. Inhaled and topical steroids are allowed. * Any contra-indication to intramuscular and /or subcutaneous injection. * Planned administration/administration of a vaccine not foreseen by the study protocol within 30 days prior to vaccination and ending 30 days after vaccination. (Vaccination with inactivated influenza vaccines, including H1N1, is allowed at any time during the study as per local recommendations). * Previous vaccination with meningococcal serogroups A, C, W-135 and Y polysaccharide vaccine within 5 years prior to vaccination. * Previous vaccination at any time with meningococcal serogroups A, C, W-135 and Y polysaccharide conjugate vaccine. * Previous vaccination with tetanus toxoid containing vaccine within 5 years prior to vaccination. * History of meningococcal disease due to serogroups A, C, W-135 or Y. * Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination. * Family history of congenital or hereditary immunodeficiency. * History of any reaction or hypersensitivity likely to be exacerbated by any component of the vaccine. * History of neurological disorders and seizures * History of Guillain-Barre syndrome. * Acute (active) clinically significant pulmonary, cardiovascular, hepatic or renal functional abnormality, as determined by physical examination or pre-existing laboratory screening tests. * Acute disease and/or fever at the time of enrolment. * Administration of immunoglobulins and/or any blood products within the 3 months preceding the first dose of study vaccine/product or planned administration during the study period. * Pregnant or lactating female. * Current chronic alcohol consumption and/or drug abuse.

Locations (1)

GSK Investigational Site

Beirut, Lebanon

Outcomes

Primary Outcomes

Vaccine Response to Meningococcal Antigens (MenA, MenC, MenW-135 and MenY)

Vaccine response for serum bactericidal assay using rabbit complement (rSBA) antibodies against Neisseria meningitides serogroups A, C , W-135, Y (rSBA-MenA, rSBA-MenC, rSBA-MenW-135 and rSBA-MenY) was defined as: for initially seronegative subjects \[rSBA titer below (\<) 1:8\], post-vaccination rSBA titer greater than or equal to (≥) 1: 32; for initially seropositive subjects with rSBA titer between 1:8 and 1:128, at least four-fold increase in rSBA titer from pre to post vaccination; and for initially seropositive subjects with rSBA titer ≥1:128, at least two-fold increase in rSBA titer from pre to post vaccination.

Time frame: One month after vaccination (Month 1)

Secondary Outcomes

Number of Subjects With rSBA-MenA, rSBA-MenC, rSBA-MenW-135 and rSBA-MenY Antibody Titers ≥ the Cut-off Value

The cut-off value for the rSBA titers was greater than or equal to (≥) 1:8.

Time frame: At Day 0 and Month 1

Number of Subjects With rSBA-MenA, rSBA-MenC, rSBA-MenW-135 and rSBA-MenY Antibody Titers ≥ the Cut-off Value

The cut-off value for the rSBA titers was greater than or equal to (≥) 1:128.

Time frame: At Day 0 and Month 1

rSBA-MenA, rSBA-MenC, rSBA-MenW-135 and rSBA-MenY Antibody Titers

Antibody titers were presented as geometric mean titers (GMTs).

Time frame: At Day 0 and Month 1

Number of Subjects With Anti-polysaccharide Meningococcal Serogroup A (Anti-PSA), Serogroup C (Anti-PSC), Serogroup W-135 (Anti-PSW-135) and Serogroup Y (Anti-PSY) Antibody Concentrations ≥ the Cut-off Value

The cut-off value for the anti-polysaccharide concentrations was greater than or equal to (≥) 0.3 micrograms per milliliter (μg/mL).

Time frame: At Day 0 and Month 1

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.